Ardelyx, Inc. Common Stock, also called Ardelyx, is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. Read More It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.